BiotechTube

AGN-242428 + AGN-231868 + Lifitegrast 5% Ophthalmic Solution

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dry Eye Disease

Conditions

Dry Eye Disease, Dry Eye Syndrome

Trial Timeline

Mar 4, 2020 → Mar 18, 2022

NCT ID
NCT04030962

About AGN-242428 + AGN-231868 + Lifitegrast 5% Ophthalmic Solution

AGN-242428 + AGN-231868 + Lifitegrast 5% Ophthalmic Solution is a phase 1/2 stage product being developed by AbbVie for Dry Eye Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04030962. Target conditions include Dry Eye Disease, Dry Eye Syndrome.

What happened to similar drugs?

20 of 20 similar drugs in Dry Eye Disease were approved

Approved (20) Terminated (1) Active (0)
✅EvolocumabHeartFlowApproved
✅Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)CelltrionApproved
✅Infliximab + Infliximab + InfliximabCelltrionApproved
✅YMC026 + PlaceboYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved
✅Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04030962Phase 1/2Completed

Competing Products

20 competing products in Dry Eye Disease

See all competitors
ProductCompanyStageHype Score
COVID-19 VaccineModernaPreclinical
0
exidavnemab + Placebo ComparatorBioArctic ABPhase 2
36
mRNA-1975ModernaPhase 2
0
mRNA-3745ModernaPhase 2
0
polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
37
UB-312 + PlaceboVaxxinityPhase 1
19
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
21
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
32
Abiprubart + PlaceboKiniksa PharmaceuticalsPhase 2
21
atomoxetine + Matching PlaceboEli LillyPhase 2
35
Rosuvastatin 40mg + PlaceboHeartFlowPre-clinical
27
EvolocumabHeartFlowApproved
29
High intensity lipid loweringHeartFlowPre-clinical
20
Apixaban 5 MG + Apixaban 2.5 MG + WarfarinArtivionPhase 3
26
LanifibranorInventivaPhase 2
29
LY450139 + PlaceboEli LillyPhase 3
40
Dulaglutide + PlaceboEli LillyPhase 3
40
raloxifene + placeboEli LillyPhase 3
40
VTX958 + VTX958 + VTX958 PlaceboVentyx BiosciencesPhase 2
21
Solanezumab + PlaceboEli LillyPhase 3
32